Clostridium difficile colitis

This early-stage trial tests an oral capsule containing a genetically modified probiotic yeast designed to neutralize toxins produced by C. diff bacteria. The study first evaluates safety in healthy adults, then in people at risk for recurrent C. diff infection. Participants take…

This study will test hyperbaric oxygen therapy (HBOT) — breathing pure oxygen in a pressurized chamber — for over 30 conditions, including long COVID, Crohn's disease, frostbite, and multiple sclerosis. Researchers will track 100 patients to see if HBOT improves their quality of …

This trial tests whether a dietary fiber called resistant potato starch can reduce the amount of drug-resistant bacteria living in the gut. The study enrolls Veterans who carry these bacteria without symptoms, and half will take the starch daily while the other half takes a place…

This study tests if xylitol, a common sweetener, can safely clear C. difficile bacteria from the gut in people with inflammatory bowel disease (IBD). About 99 adults with mild or inactive IBD will take either a low or high dose of xylitol or a placebo for four weeks. Researchers …

This pilot study tests whether xylitol, a common sugar alcohol, can safely clear C. difficile bacteria from the guts of people with inflammatory bowel disease (IBD). About 69 adults with mild or inactive IBD will take different doses of xylitol for up to 8 weeks. Researchers will…

This study compares two antibiotics, fidaxomicin and vancomycin, to see which one is better at clearing C. difficile bacteria from the gut in people with inflammatory bowel disease (IBD). About 60 adults with IBD will take one of the two antibiotics for 10 days and be followed fo…

This trial tests whether giving children a probiotic called Saccharomyces boulardii alongside a common antibiotic can prevent diarrhea, a frequent side effect. Children aged 6 months to 5 years with upper respiratory infections will receive either the antibiotic alone or the anti…

This early-phase trial tests whether adding Ursodeoxycholic Acid (UDCA) to standard antibiotics can prevent Clostridioides difficile (C. diff) infection from returning. About 30 adults with C. diff and risk factors for recurrence will take UDCA three times daily for up to eight w…

This study looks at adults who had a C. diff infection and were treated with either a fecal transplant (FMT) or antibiotics alone. Researchers want to see if FMT leads to healthier gut bacteria and fewer health problems years later. Participants will give blood, stool, and urine …

This study will give fecal transplants to 90 people with recurrent C. difficile infection, ulcerative colitis, or metabolic syndrome. Researchers will use advanced tests on stool and tissue samples to track how donor bacteria settle in the gut and interact with the host. The goal…